enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Tuesday, April 22^nd at 4:00 PM ET

Text size:

IRVINE, CA / ACCESS Newswire / April 16, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in the Virtual Investor Closing Bell Series on Tuesday, April 22, 2025 at 4:00 PM ET.

As part of the event, Mr. Berman will provide a corporate overview and discuss the Company's portfolio of novel implantable replacement venous valve technologies, the VenoValve® and enVVe®, for the treatment of severe deep venous CVI. In addition to the moderated discussion, there will be a live question and answer session. Mr. Berman will answer as many questions as possible in the time allowed.

A live video webcast of the presentation will be available on the Events page of the Company's website (www.envveno.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. CVI occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal and become chronic. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the SAVVE U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.

INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
[email protected]
(908) 824-0775

MEDIA CONTACT:
Glenn Silver, FINN Partners
[email protected]
(973) 818-8198

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

O.Johnson--AMWN

BCC	0.39%	84.15	$
CMSD	0.39%	23.32	$
JRI	0.08%	12.89	$
RBGPF	100%	64	$
CMSC	0.17%	22.95	$
BTI	1.39%	58.09	$
NGG	0.53%	87.42	$
BCE	-0.92%	23.88	$
RIO	0.76%	99.61	$
GSK	-2.19%	54.44	$
RELX	1.09%	36.53	$
BP	-0.22%	46.25	$
RYCEF	-0.78%	15.3	$
VOD	0.06%	15.63	$
AZN	-1.34%	189.75	$

American Marconi Wireless News - enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Featured

Four Independent Studies Validate The Blight Tolerance Of Darling American Chestnut Trees

Good Driver Club Redesigns Its Website and App to Bring Transparency into Clearer View

Good Driver Club Publishes Eligible Events in Full Each Monday

The Story Behind Good Driver Club: Why Good Drivers Deserve to Keep More